Docstoc

Collaboration agreement between

Document Sample
Collaboration agreement between Powered By Docstoc
					             Sanofi-aventis and IFMT Sign Agreement to Develop
                   Better Access to Epilepsy Care in Laos

Vientiane, Laos, May 27, 2009 - Sanofi-aventis and the IFMT (Institut de la Francophonie pour la
Médecine Tropicale) announced today the signing of an agreement, whereby sanofi –aventis will
support the development of a national program for Epilepsy treatment in Laos, being put in place by
IFMTwith various partners, for the Laos Ministry of Health.

Epilepsy is the most widespread neurological disorder in the world, aside from migraine(1). It is
estimated that there are 50,000 patients with epilepsy in Laos, and that only 10% are receiving
treatment for their condition(2).

The objective of this program is to improve care of patients with epilepsy in Laos through:
    Training of Healthcare professionals
    Setting up clinics for epilepsy diagnosis and management
    Improving availability and accessibility of Anti-Epileptic Drugs (AEDs)
    Educating the community about epilepsy

Under the terms of the agreement, sanofi-aventis will provide funding of €60 thousand over three
years to develop health professional training and epilepsy awareness programs.

Sanofi-aventis plans also, through its Access to Medicines program, to make available AEDs, with a
preferential pricing policy.

IFMT will conduct the epidemiological survey and all field activities necessary for the development
of an efficient campaign against Epilepsy in Laos.

“This new Impact Epilepsy program in Laos is the sixth to be developed by our group through our
Access to Medicines policy, acknowledging the engagement of our Group to fight Epilepsy in
developing countries as well as in the rest of the world,” said Robert Sebbag , Vice President for
Access to Medicines of sanofi-aventis.

“The support of sanofi-aventis will enable us to accelerate the implementation of a national epilepsy
care program in Laos,” said Hubert Barennes, IFMT Training and Research coordinator



Ref : (1).HO, « Atlas-Epilepsy Care in the world 2005 »
       (2) Barennes H. et al ; Neurology Asia 2008; 13:27-31
About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes
therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris
(EURONEXT : SAN) and New York (NYSE : SNY).


About the Institut de la Francophonie pour la Médecine Tropicale
Established in 2000, the Francophone Institute of Tropical Medicine conducts a 2-year Masters
Degree Program in Tropical Medicine and International Health for more than 130 doctors coming
from Laos, China, Vietnam, Cambodia and Madagascar. Since 2003, the institute has collaborated
with various partners and Lao Institutions on epilepsy studies with the overall aim to develop the
scientific basis for guiding appropriate intervention.


Media Contacts:

Sanofi-aventis
Name: Dr Benedict Blayney, Vice President, Medical Affairs, Asia Pacific
Tel: +65 812 66615
Email: benedict.blayney@sanofi-aventis.com


Institut de la Francophonie pour la Médecine Tropicale
Dr H.Barennes, MD, PhD, Research director
Tel : 00856 21 219346, 00856 202590024 (mobile)
Email : hubert.barennes@auf.org